Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Omada Health vs RxSpan MD

Omada Health
Graded #435

Lower grade

vs+31.199999999999996
RxSpan MD
Graded #4

Higher grade

The verdict

RxSpan MD takes it — 86.8/100 to 55.6/100.

RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A physician-led telehealth under board-certified founder Dr. John Diaz with a broad GLP-1 menu — compounded semaglutide and tirzepatide by injection or oral capsule, plus a brand-name lane and microdosing — on transparent all-inclusive pricing to all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRxSpan MD +41
45
86
Dose & formulationRxSpan MD +49
40
89
Clinical oversightRxSpan MD +11
77
88
Labs & monitoringRxSpan MD +22
61
83
FulfillmentRxSpan MD +27
62
89
Contract termsRxSpan MD +30
55
85
Omada Health · left barRxSpan MD · right bar

The numbers

MetricOmada HealthRxSpan MD
WeighScore55.6/10086.8/100
GradeCB
Scorecard rank#435#4
SemaglutideNot disclosedFrom $194/mo
TirzepatideNot disclosed$329/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Omada Health

Graded #435 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program
RxSpan MD

Graded #4 · B

Strengths

  • Available in all 50 states
  • Transparent, all-inclusive published pricing — consult, medication, supplies, shipping and support, cancel anytime, from ~$194/mo compounded semaglutide on an annual plan
  • Both injectable and a real oral (capsule) route, plus compounded and an advertised brand-name lane
  • Physician-led by a named, board-certified founder (Dr. John Diaz) with 24/7 messaging and coaching

Where it loses points

  • Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
  • Published pricing is for the compounded line — brand-name pricing isn’t itemized
  • A prescription isn’t guaranteed — a provider reviews eligibility after checkout

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard